About GDNF family receptor alpha-2
GDNF family receptor alpha-2 (GFRA2) is a protein
from Homo sapiens identified by UniProt accession
O00451, 464 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | GDNF family receptor alpha-2 |
| UniProt accession | O00451 |
| Gene | GFRA2 |
| Organism | Homo sapiens |
| Length | 464 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (93)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.42
- trait in response to pazopanib · score 0.33
- GDNF family receptor alpha-2 measurement · score 0.33
- breast adenocarcinoma · score 0.29
- DNA methylation · score 0.27
- frontotemporal dementia · score 0.26
- self reported educational attainment · score 0.26
- neurodegenerative disease · score 0.25
- fat body mass · score 0.20
- serum albumin measurement · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00451-F1 | alphafold | PREDICTED | 74.99 | — |
Amino-acid sequence (464 residues)
MILANVFCLF FFLDETLRSL ASPSSLQGPE LHGWRPPVDC VRANELCAAE SNCSSRYRTL RQCLAGRDRN TMLANKECQA ALEVLQESPL YDCRCKRGMK KELQCLQIYW SIHLGLTEGE EFYEASPYEP VTSRLSDIFR LASIFSGTGA DPVVSAKSNH CLDAAKACNL NDNCKKLRSS YISICNREIS PTERCNRRKC HKALRQFFDR VPSEYTYRML FCSCQDQACA ERRRQTILPS CSYEDKEKPN CLDLRGVCRT DHLCRSRLAD FHANCRASYQ TVTSCPADNY QACLGSYAGM IGFDMTPNYV DSSPTGIVVS PWCSCRGSGN MEEECEKFLR DFTENPCLRN AIQAFGNGTD VNVSPKGPSF QATQAPRVEK TPSLPDDLSD STSLGTSVIT TCTSVQEQGL KANNSKELSM CFTELTTNII PGSNKVIKPN SGPSRARPSA ALTVLSVLML KLAL
Explore GDNF family receptor alpha-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets